nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Acknowledgement to Referees
|
|
|
|
14 |
6 |
p. 627-630 |
artikel |
2 |
Acknowledgement to Referees
|
|
|
|
14 |
6 |
p. 627-630 |
artikel |
3 |
Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study
|
Legué, Laura M. |
|
|
14 |
6 |
p. 699-705 |
artikel |
4 |
Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study
|
Feyerabend, Susan |
|
|
14 |
6 |
p. 681-688 |
artikel |
5 |
Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC
|
Dhillon, Sohita |
|
|
14 |
6 |
p. 759-768 |
artikel |
6 |
Correction to: Combination Treatment with an Antibody–Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian Cancer
|
Wan, Y. Louise |
|
|
14 |
6 |
p. 769 |
artikel |
7 |
Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study
|
Yang, Zhengquan |
|
|
14 |
6 |
p. 719-728 |
artikel |
8 |
Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab
|
Lim, Huezin H. |
|
|
14 |
6 |
p. 743-748 |
artikel |
9 |
First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options
|
Loo, Vivian |
|
|
14 |
6 |
p. 639-645 |
artikel |
10 |
PARP Inhibition in Cancer: An Update on Clinical Development
|
Sachdev, Esha |
|
|
14 |
6 |
p. 657-679 |
artikel |
11 |
Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials
|
Paliard, Xavier |
|
|
14 |
6 |
p. 631-637 |
artikel |
12 |
Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study
|
Kim, Jwa Hoon |
|
|
14 |
6 |
p. 689-697 |
artikel |
13 |
Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study
|
Kim, Jwa Hoon |
|
|
14 |
6 |
p. 689-697 |
artikel |
14 |
Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer
|
Heo, Young-A |
|
|
14 |
6 |
p. 749-758 |
artikel |
15 |
Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study
|
Lang, David |
|
|
14 |
6 |
p. 707-717 |
artikel |
16 |
Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab
|
Kolberg, Hans-Christian |
|
|
14 |
6 |
p. 647-656 |
artikel |
17 |
Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice
|
Czarnecka, Anna M. |
|
|
14 |
6 |
p. 729-742 |
artikel |